Castle Biosciences
D

CSTL

33.140
USD
-0.03
(-0.09%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
11,129
الربح لكل سهم
-1
العائد الربحي
-
P/E
-52
حجم السوق
1,012,410,662
نظرة عامة
أصول ذات صلة
BP
BP
D
BP plc
51.320
1.280(2.56%)
51.290-0.030(-0.06%)
CNQ
CNQ
D
Canadian Natural Resources Limited
55.070
1.170(2.17%)
COP
COP
D
ConocoPhillips
150.790
5.140(3.53%)
151.150+0.360(+0.24%)
CVX
CVX
D
شيفرون
233.210
6.550(2.89%)
233.340+0.130(+0.06%)
SCO
SCO
D
Proshares Trust Ii Ultrashort Bloomberg Crude Oil
15.920
-0.620(-3.75%)
15.9200.000(0.00%)
TOT
TOT
D
Lionshares U.S. Equity Total Return ETF
23.876
-0.112(-0.47%)
23.8760.000(0.00%)
XOM
XOM
D
إكسون موبيل
183.190
4.990(2.80%)
183.250+0.060(+0.03%)
المزيد

العنوان: Castle Biosciences

القطاع: الرعاية الصحية
الصناعة: Diagnostics & Research
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.